Acadian Asset Management LLC increased its position in shares of Aptose Biosciences Inc (NASDAQ:APTO) (TSE:APS) by 316.9% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 44,421 shares of the biotechnology company’s stock after acquiring an additional 33,766 shares during the quarter. Acadian Asset Management LLC owned about 0.17% of Aptose Biosciences worth $100,000 as of its most recent SEC filing.

Aptose Biosciences Inc (NASDAQ:APTO) opened at $2.77 on Friday. Aptose Biosciences Inc has a one year low of $0.78 and a one year high of $3.90. The firm has a market cap of $75.52, a P/E ratio of -4.26 and a beta of 2.84.

Aptose Biosciences (NASDAQ:APTO) (TSE:APS) last announced its quarterly earnings results on Tuesday, November 14th. The biotechnology company reported ($0.11) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.13) by $0.02. equities analysts predict that Aptose Biosciences Inc will post -0.61 earnings per share for the current fiscal year.

Several research analysts recently weighed in on the stock. HC Wainwright set a $4.00 price objective on shares of Aptose Biosciences and gave the stock a “buy” rating in a research note on Wednesday, November 15th. ValuEngine raised shares of Aptose Biosciences from a “strong sell” rating to a “sell” rating in a research note on Tuesday, October 31st. Zacks Investment Research raised shares of Aptose Biosciences from a “hold” rating to a “buy” rating and set a $2.00 price objective on the stock in a research note on Friday, November 17th. Canaccord Genuity set a $7.00 price objective on shares of Aptose Biosciences and gave the stock a “buy” rating in a research note on Wednesday, November 15th. Finally, Roth Capital reissued a “buy” rating and set a $5.00 price objective on shares of Aptose Biosciences in a research note on Monday, October 23rd. Two analysts have rated the stock with a sell rating, one has given a hold rating and three have given a buy rating to the stock. Aptose Biosciences presently has an average rating of “Hold” and an average target price of $5.00.

ILLEGAL ACTIVITY NOTICE: “Aptose Biosciences Inc (APTO) Position Lifted by Acadian Asset Management LLC” was published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this piece of content on another site, it was illegally stolen and republished in violation of U.S. & international copyright laws. The legal version of this piece of content can be viewed at https://www.thecerbatgem.com/2018/02/10/aptose-biosciences-inc-apto-position-lifted-by-acadian-asset-management-llc.html.

About Aptose Biosciences

Aptose Biosciences Inc (Aptose) is a clinical-stage biotechnology company. The Company is engaged in the development of anticancer drugs that target specific epigenetic processes and signal transduction abnormalities that underlie a particular life-threatening malignancy. Its product pipeline includes cancer drug candidates that exert activity as stand-alone agents and that enhance the activities of other anticancer agents without causing overlapping toxicities.

Receive News & Ratings for Aptose Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptose Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.